uploads///Chart  ETFs

Behind Pharmaceutical ETF Performances in 3Q17

By

Oct. 17 2017, Published 3:56 p.m. ET

Pharmaceuticals ETFs

Pharmaceutical ETFs are publicly traded securities designed for investors who don’t have the capacity to hold too many stocks but are interested in a diversification of their investments within the pharmaceutical sector. Such ETFs not only diversify a portfolio but also have other benefits like the ability to sell short, buy on margin, and purchase even a single unit. ETFs also have a lower expense ratio than mutual funds.

Article continues below advertisement

XLV

The Healthcare Select Sector SPDR ETF (XLV) is focused on pharmaceuticals and biotechnology companies. It’s been operational since 1998 and had a market capitalization of ~$17.7 billion on October 16, 2017.

XLV’s price rose ~3.8% in 3Q17, while its YTD (year-to-date) returns are at 19.5% as of October 16, 2017.

PPH

The VanEck Vectors Pharmaceuticals ETF (PPH) is focused on large drug manufacturing companies. The fund has been operational since 2011, and its market capitalization was ~$305.4 million on October 16, 2017.

PPH fell marginally in 3Q17, while its YTD returns are at 10.0% as of October 16.

Article continues below advertisement

IHE

The iShares US Pharmaceuticals ETF (IHE) is focused on large drug manufacturers like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ). IHE has been operational since 2006 and had a market capitalization of ~$623.6 million as of October 16, 2017. 

IHE’s price rose ~2.4% in 3Q17, while its YTD returns are at 11.6% as of October 16.

PJP

The PowerShares Dynamic Pharmaceuticals ETF (PJP) is focused on both drug manufacturers and biotechnology companies. The fund has been operational since 2005 and had a market capitalization of ~$729.6 million on October 16.

PJP’s holdings include AbbVie (ABBV) and Gilead Sciences (GILD). The ETF’s price rose ~5.3% in 3Q17, while its YTD returns are 17.8% as of October 16.

XPH

The SPDR S&P Pharmaceuticals ETF (XPH) is focused on both drug manufacturers and biotechnology companies. This fund tracks an index that represents the pharmaceutical sub-industry portion of the S&P Total Markets Index.

XPH has been operational since 2006 and had a market capitalization of ~$430.8 million on October 16. The fund’s price rose marginally in 3Q17, while its YTD gains are at 10.2% as of October 16.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.